Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors K.R. Webster, V. K Goel, I. NJ Hung, G. S Parker, J.Staunton, M. Neal, J. Molter, G.G Chiang, K. A. Jessen, C. J Wegerski, S. Sperry, V. Huang, J. Chen, P. A Thompson, J. R Appleman, S. E Webber, P. A Sprengeler, S. H Reich
Title eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)
Journal Blood Dec 2015, 126 (23) 1554
Abstract Text


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Tomivosertib Tomivosertib 2 6
Drug Name Trade Name Synonyms Drug Classes Drug Description
Tomivosertib eFT508 MNK1/2 Inhibitor 3 Tomivosertib (eFT508) inhibits MNK1 and MNK2, potentially resulting in decreased tumor cell proliferation and tumor growth, and disrupts translation of PD-L1 (CD274) through inhibition of EIF4E phosphorylation (PMID: 30643286).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown diffuse large B-cell lymphoma not applicable Tomivosertib Preclinical Actionable In a preclinical study, eFT508 inhibited proliferation of diffuse large B-cell lymphoma cell lines in culture (Blood Dec 2015, 126 (23) 1554). detail...
MYD88 act mut diffuse large B-cell lymphoma predicted - sensitive Tomivosertib Preclinical - Cell line xenograft Actionable In a preclinical study, eFT508 demonstrated anti-tumor activity in two diffuse large B-cell lymphoma cell line xenograft models, both harboring MYD88 activating mutations (Blood Dec 2015, 126 (23) 1554). detail...